Heart failure results in high adult hospitalization and mortality rates worldwide. In developed countries, the prevalence of heart failure is reported in up to 2% of the total adult population and 10% in those older than 70 years.1) Furthermore, the mortality of heart failure is very high after initial diagnosis, around 30% at 1 year and 50% at 5 years.2) In the acute heart failure state, in-hospital mortality is reported at 28%, while that of cardiogenic shock is 40% to 80%.3)
Cardiac resynchronization therapy (CRT) has been established as an effective treatment for symptomatic advanced heart failure patients with wide QRS duration despite having exhausted all other optimal medical therapy.4) CRT can improve hospitalization and mortality rates by correcting unfavorable left ventricular hemodynamics or dyssynchrony.5)6) However, since nearly one-third of patients have not experienced any benefit from CRT implantation at a significant financial cost, identifying CRT responders remains a challenging task in clinical practice.7)8) Improvements of left ventricular systolic function and synchrony were commonly evaluated in previous studies. The right ventricle (RV) is also a crucial contributor to prognosis of advanced heart failure.9)10) Therefore, the prognostic value of RV function for CRT referral patients is as yet to be identified and needs further evaluation through clinical study.
In this issue of Journal of Cardiovascular Imaging, Bragança et al.11) investigated the clinical correlations and prognostic values of right ventriculo-arterial coupling (RV-PA) in heart failure patients undergoing CRT. They demonstrated that RV-PA coupling estimated by tricuspid annular plane systolic excursion and pulmonary artery systolic pressure ratio (TAPSE/PASP) showed excellent discriminative power for predicting response to CRT, and that PASP was independently associated with overall mortality in this group of heart failure patients. In addition, they suggested a novel cut-off value of baseline TAPSE/PASP ratio as 0.44 mm/mmHg for detection of a CRT non-responder, with good accuracy (area under the curve 0.76). Also, among CRT responders, improvements of RV-PA coupling were noted during follow-up in those showing elevated TAPSE and TAPSE/PASP ratio. However, this study has limitations of a small sample size and performed at a single center with a retrospective design in which selection bias was inevitable. Moreover, the echocardiographic-based TAPSE/PASP was not compared with the gold-standard method of right heart catheterization or cardiac magnetic resonance. Nonetheless, these findings provide a basis for consideration of right heart and pulmonary circulation in CRT referred patients using the easily performed echocardiographic-based TAPSE/PASP ratio method. This approach deserves further exploration.
In conclusion, Bragança et al.11) found that RV-PA coupling as estimated by TAPSE/PASP ratio can be used as a significant prognostic marker in heart failure patients undergoing CRT. Further studies are warranted in numbers large enough to be statistically significant when using a prospective design.
References
1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93:1137–1146. PMID: 17699180.
2. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000; 102:1126–1131. PMID: 10973841.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33:1787–1847. PMID: 22611136.
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37:2129–2200. PMID: 27206819.
5. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361:1329–1338. PMID: 19723701.
6. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352:1539–1549. PMID: 15753115.
7. Chinitz JS, d'Avila A, Goldman M, Reddy V, Dukkipati S. Cardiac resynchronization therapy: who benefits? Ann Glob Health. 2014; 80:61–68. PMID: 24751566.
8. Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009; 53:765–773. PMID: 19245967.
9. Di Bella G, Siciliano V, Aquaro GD, et al. Right ventricular dysfunction: an independent and incremental predictor of cardiac deaths late after acute myocardial infarction. Int J Cardiovasc Imaging. 2015; 31:379–387. PMID: 25348657.
10. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001; 37:183–188. PMID: 11153735.
11. Bragança B, Trêpa M, Santos R, et al. Echocardiographic assessment of right ventriculo-arterial coupling: clinical correlates and prognostic impact in heart failure patients undergoing cardiac resynchronization therapy. J Cardiovasc Imaging. 2020; 28:109–120. PMID: 32052609.